 forefront of discussions at the CoR's October plenary session and the 2022 European Week of Regions and Cities.
During a plenary debate on COP27, the upcoming United Nations Climate Change Conference (UNFCCC), CoR members called for the EU's response to the energy crisis not to undermine the EU's climate ambition. The 3rd meeting of the Zero Pollution Stakeholder Platform also took place this week, with cities and regions recalling their key role in reducing pollution across the EU. The need to decarbonise transport to reduce carbon emissions and improve citizens' health was amongst this week's key concerns.
Following the publication of the 8th Cohesion Report in February, CoR members recalled the paramount role of cohesion policy in reducing disparities between EU regions while helping the Union to achieve a just transition, reducing the dependence from fossil fuels and becoming more energy-independent. Through the adoption of an opinion on a 'Just and Sustainable Transition in the context of the coal and energy intensive regions' by rapporteur Sari Rautio (FI/EPP), members stressed the need to support the energy and manufacturing sector, industries and SMEs in their conversion towards climate-neutrality.
The European Committee of the Regions 2022 EU annual report on the state of regions and cities indicates that local and regional authorities are facing unpredictable and extreme weather conditions more frequently and increasingly complex climate-change risks, due to global warming deregulating the climate. The climate crisis is listed amongst the current biggest challenges for local and regional authorities, in addition to the economic recovery from the COVID-19 pandemic and the energy and inflation crisis.
The 2022 CoR annual report specifies that global warming has a severe direct impact on GDP growth. In a 3°C scenario, net losses for countries north of the Alps are estimated to be 0.2% to 0.6% GDP while southern and southeast European countries' net loss may total up to 2.8% of GDP. Between 1980 and 2020, economic damages from climate-related events amounted to at least €419 billion in the EU (economic loss average of €12 billion per year) and affected nearly 50 million people. Over 80% of losses and 95% of fatalities can be attributed to natural disasters caused by weather and climate-related extremes. Climate damages could reach €170 billion per year, warns the CoR's annual report, since floods, wildfires, and extreme heat are increasing rapidly.
The Zero Pollution Stakeholder Platform is a joint initiative of the CoR and the European Commission. Supporting local and regional authorities deploying concrete measures to reduce pollution is a key objective of Green Deal Going Local, the CoR flagship initiative to place cities and regions at the heart of the EU's transition towards climate-neutrality.
On October 6, the European Committee of the Regions elected Rafał Trzaskowski (PL/EPP), Mayor of Warsaw, as new chair of the CoR's ENVE Commission and Green Deal Going Local working group.
Click here to access the October plenary photo album.
Mom, Dad? I have something to tell you. 



Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) have earned a consensus rating of “Hold” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $26.00.
A number of research analysts recently issued reports on RXRX shares. Zacks Investment Research raised Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, March 16th. The Goldman Sachs Group cut their price target on Recursion Pharmaceuticals from $32.00 to $10.00 and set a “neutral” rating for the company in a report on Thursday, March 24th. Finally, SVB Leerink cut Recursion Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the company from $32.00 to $10.00 in a report on Friday, March 4th.
Shares of NASDAQ RXRX traded down $1.12 during midday trading on Friday, reaching $6.68. 52,150 shares of the company traded hands, compared to its average volume of 1,356,780. The firm has a market cap of $1.14 billion and a PE ratio of -2.86. The stock’s 50-day simple moving average is $9.16 and its 200-day simple moving average is $15.18. Recursion Pharmaceuticals has a 12 month low of $5.80 and a 12 month high of $42.81.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) last issued its quarterly earnings data on Wednesday, March 23rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.07). Recursion Pharmaceuticals had a negative net margin of 1,832.18% and a negative return on equity of 48.07%. Equities analysts expect that Recursion Pharmaceuticals will post -0.95 earnings per share for the current fiscal year.
In related news, CEO Christopher Gibson sold 19,858 shares of Recursion Pharmaceuticals stock in a transaction dated Monday, January 31st. The stock was sold at an average price of $11.73, for a total value of $232,934.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders sold 836,858 shares of company stock valued at $6,831,044.
Several institutional investors have recently bought and sold shares of the company. Moors & Cabot Inc. bought a new stake in Recursion Pharmaceuticals in the 3rd quarter valued at approximately $28,000. Morgan Stanley bought a new stake in Recursion Pharmaceuticals in the 2nd quarter valued at approximately $41,000. Itau Unibanco Holding S.A. bought a new stake in Recursion Pharmaceuticals in the 4th quarter valued at approximately $44,000. Rockefeller Capital Management L.P. lifted its stake in Recursion Pharmaceuticals by 105.0% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 2,050 shares of the company’s stock valued at $47,000 after acquiring an additional 1,050 shares in the last quarter. Finally, Baldwin Brothers LLC MA bought a new stake in Recursion Pharmaceuticals in the 4th quarter valued at approximately $47,000. Institutional investors own 37.71% of the company’s stock.Participation: This workshop and masterclass will accommodate a limited number of participants.
Readings: List of readings will be available to participants by early April.
Project descriptions and a reading list will be circulated in April.
In light of the present situation and considerations of health and travel, we are postponing the Ph.D. course “Multimodal research in communication, organization and management studies,” which was to be held June 8th – 10th 2020. It is our hope that we’ll be able to offer the course in the autumn of 2020 or spring of 2021.
We will get back to you with more information, when we know more.
This masterclass is aimed at doctoral students and staff interested in organizational semiotics, that is, the application of multimodal research to understanding organizational communication as well as the fields of organization and management studies.
The class will focus on the increasingly important role of multimodal communication in specific aspects of institutional life such as innovation, organizational identity, the 17 UN Sustainable Development Goals, corporate social responsibility and the legitimation of organizations and their activities. The course will also provide practical guidance in establishing and conducting research in and with actual organizations.
Five elements will be combined in this course: (1) an introduction to the social semiotic approach to multimodal analysis (Prof. Van Leeuwen); (2) the role of multimodal processes in the structures, relations and identities of contemporary organizations (Prof. Meyer); (3) multimodal organizational communication with a focus on sustainability (Assoc. Prof. Nørgaard); (4) the role of spatial design in organizational communication (Assoc. Prof. Aiello), and (5) building a framework for practical and effective research engagement with organizations, including issues such as data collection and commercial confidentiality (Prof. Höllerer).
Each masterclass session will include an introductory lecture and a hands-on workshop giving students an opportunity to work with real data. The course will also provide for individual consultations with the presenters and short presentations (appr. 10 minutes) by attending PhD students.
Send a brief CV and a 1-2-page description of your project to |||EMAIL_ADDRESS||| indicating specific questions that you would like to discuss, and whether you would like a consultation (appr 20 mins) with one or more of the teachers.
I want to join the Navy and my wife has seizures.

I honestly get excited about the idea of joining the Navy but the main reason I want to join is for the health insurance the military has to offer since my wife's health is poor and I don't want to go bankrupt from medical debt at a young age, we're both 25 btw and she's fortunately on her dads insurance. I'm worried of the fact that my wife will be alone if I get accepted. We'll be living on